VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Titel:
VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Auteur:
Moreau, P. Dimopoulos, M.A.C. Mikhael, J. Yong, K. Capra, M. Facon, T. Hajek, R. Špička, I. Casca, F. Mace, S. Singh, E. Risse, M-L. Martin, T.